Breaking News:

On October 21, 2019, during UEG week held in Barcelona, ABIVAX has reported Impressive 12-month Efficacy and Safety Data from ABX464 Ulcerative Colitis Maintenance Study.

Information is available at the following link: http://www.abivax.com/investors/ueg-week-2019/

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment C
  • Type of Listing: continuous
  • Number of outstanding shares: 11 808 939 as of 30 September 2019
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

LifeSci Capital Alpha Series:

Adam Evertts & David Sherman

Contact Adam Evertts / Contact David Sherman

 

goetzpartners securities:

Chris Redhead

Contact Chris Redhead

Kepler Cheuvreux:

Damien Choplain

Contact Damien Choplain

Download report

 

Portzamparc:

Christophe Dombu

Contact Christophe Dombu

Download report

NIBC:

Dylan van Haaften & Anita Ye

Contact Dylan van Haaften / Contact Anita Ye

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254